Expert Interview
A look at novel therapeutics in development for NMIBC, including; Cretostimogene, TAR-200 and the TAR-210 Erdafitinib Intravesical Delivery System.
Ticker(s): CGON, JNJInstitution: Urology Associates, P.C
- Co-director of Urologic Associates, P.C and Clinical Associate Professor of Urology at Vanderbilt
- Treats 500 NMIBC patients per year
- Clinical and Research interest in immunotherapy and novel therapies for patients with complex urinary tract cancers and has experience with kidney, prostate, and bladder surgery with an emphasis on minimally-invasive cancer surgery.
On a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for Cretostimogene in NMIBC? TAR-200? TAR-210?
Added By: sara_adminWhat percentage of your patients would be eligible for Cretostimogene, if approved in the future?
What endpoints are you hoping to see in future Phase 3 studies of these candidates?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
